Yanyan Cui, Ph.D.

Principal Scientist
Stoke Therapeutics, Inc.

Yanyan Cui (Ph.D) works as Principal Scientist in DMPK/ClinPharm of Stoke Therapeutics to support TOX/Clinical studies in development new drugs from ASO. Beyound bioanalysis and PK/TK analysis, he wored on anti-drug-antibody (ADA) investigation in DMPK. A successful ADA method development will be shared in 2022 AAPS meeting.

Poster(s):

• (M1130-06-40) Development and Validation of a Sensitive Hybridization-Electrochemiluminescence (H-ECL) Method for Quantitation of STK-002, an Antisense Oligonucleotide, in Human Serum
  Monday, October 23, 2023

  11:30 AM – 12:30 PM ET